“ADG20, a novel monoclonal antibody concentrating on the spike protein of SARS-CoV-2 and associated coronaviruses, is in international medical improvement by Adagio as a single agent for each the therapy and prevention of COVID-19, the illness attributable to the SARS-CoV-2 virus, its variants, in addition to future variants which will emerge,” it added.
Preliminary information point out that ADG20 may present each fast and sturdy safety in opposition to COVID-19 for as much as one 12 months, Biocon Biologics stated.
With its potential to deal with resistant variants, together with the Delta variant, and its capacity to be administered simply as a single, intramuscular injection within the outpatient setting, ADG20 is uniquely poised to deal with the present want for an efficient, protected and handy remedy for COVID-19, it added.
“We’re very proud to accomplice with Adagio in our shared mission to supply inexpensive entry to a best-in-class antibody remedy for individuals affected by SARS-CoV-2,” Biocon Biologics Government Chairperson Kiran Mazumdar-Shaw stated.
This partnership with Adagio, “aligns our joint imaginative and prescient of bringing superior biologic therapies to hundreds of thousands of sufferers in low and center earnings nations,” she added.
Biocon Biologics has a complete COVID-19 portfolio that addresses the wants of sufferers at completely different levels of the illness spectrum — gentle, average, extreme and significant, the assertion stated.
Throughout the pandemic in India, over 50,000 sufferers benefited from its COVID-19 medicine that included Remdesevir, Itolizumab and Cytosorb, it added.
Adagio plans to hunt Emergency Use Authorization (EUA) within the US as early as the primary quarter of 2022. Beneath the phrases of the deal, Biocon Biologics will get entry to the medical and nonclinical information from Adagio’s EUA submission to the US Meals and Drug Administration to hunt approvals within the rising markets, the assertion stated.